ATLANTA (AP/WAOK) – The Food and Drug Administration is offering new survival hope to those suffering from late-stage metastatic breast cancer. The agency has given its blessing to a new drug that will be known by the brand name Kadcyla. In its approval announcement issued Friday, the FDA said the new drug is a therapy for women with HER2-positive breast cancer. Kadcyla is a combination of two drugs commonly known as Herceptin and the powerful chemotherapy drug called DM1. The treatment will be expensive. Kadcyla will cost nearly ten-thousand dollars each month and the regimen is generally just over nine months. Genentech, which developed the drug, says the company is working to get it out to patients “as soon as humanly possible.”

Comments

Leave a Reply

Please log in using one of these methods to post your comment:

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s

More From CBS Atlanta

Haunted Historical Sites In The South
Where To See Live Jazz In Atlanta

Watch & Listen LIVE